Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Patient usefulness rating
87/100
Conditions
Cholangiocarcinoma, IDH Mutation
Eligibility
Inclusion Criteria: 1. Patient\* provides signed informed consent. 2. Patient is ≥ 18 years at the time of given informed consent. 3. Patient has histologically documented curatively resected intrahepatic cholangiocarcinoma, without metastatic…
AI-generated summary
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma is being studied. Conditions: Cholangiocarcinoma, IDH Mutation • Eligibility: Inclusion Criteria: 1. Patient\* provides signed informed consent. 2. Patient is ≥ 18 years at the time of given informed consent. 3. Patient has histologically documented curatively resected…. Goal: This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 70
Sponsor
Eli Lilly and Company
Patient usefulness rating
70/100
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Eligibility
Inclusion Criteria: * Advanced IDH mutant hematologic malignancy including: \-- For Dose Escalation Arm C and Dose Expansion Cohort 5: * Patients with newly diagnosed AML who are 75 years or older…
AI-generated summary
- This is a phase 1, open-label study testing an oral drug called LY3410738, which targets IDH1 and IDH2 mutations in adults with advanced blood cancers.
- The study has two parts: dose escalation to find the maximum tolerated dose, followed by dose expansion to further assess safety and signs of activity in five cohorts.
- Eligible participants include people with IDH-mutant advanced hematologic malignancies who have received prior therapy; in some arms, older AML patients or relapsed/refractory AML patients (US only) may enroll.
- Key exclusions include active infection or active CNS disease, recent stem cell transplant or CAR-T therapy, pregnancy, and certain drug interactions or other serious conditions.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Neonc Technologies, Inc.
Patient usefulness rating
87/100
Conditions
Glioblastoma Multiforme
Eligibility
Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or recurrent, primary or secondary…
AI-generated summary
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or…. Goal: This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Servier Bio-Innovation LLC
Patient usefulness rating
50/100
Conditions
IDH1-mutant Cholangiocarcinoma
Eligibility
Inclusion Criteria: * Male of female participant age ≥ 18 years old * Have documented IDH1 gene-mutated disease based on local testing procedure (R132C/L/G/H/S mutations variants tested) * Eastern Cooperative Oncology Group…
AI-generated summary
- The trial tested the safety and early anti-cancer activity of a three-drug combo—ivosidenib with nivolumab and ipilimumab—in adults with nonresectable or metastatic IDH1-mutant cholangiocarcinoma.
- It started with a safety lead-in to find the recommended combination dose and planned a dose-expansion to assess efficacy, but the expansion was never started because the study was terminated.
- Eligibility required adults 18 or older with IDH1-mutant cholangiocarcinoma, ECOG 0–1, at least one measurable tumor, and nonresectable/metastatic disease not eligible for curative therapy (prior local therapy allowed under certain conditions).
- Key exclusions included prior IDH inhibitors or prior immune checkpoint inhibitors other than anti-PD-1/PD-L1, active autoimmune disease or systemic immunosuppression, unresolved toxicity from prior therapy, and symptomatic brain metastases requiring steroids.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
M.D. Anderson Cancer Center
Patient usefulness rating
80/100
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Eligibility
Inclusion Criteria: 1. Pathologically proven CCUS or lower-risk MDS/CMML. 1. CCUS is defined as the presence of cytopenia (absolute neutrophil count \< 1.8 x 10\^9/L, hemoglobin \< 13 g/dL in males or…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Institut de Recherches Internationales Servier
Patient usefulness rating
57/100
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
Eligibility
Key Inclusion Criteria: 1. Dose Escalation 1. Subjects must have histologically or cytologically confirmed, IDH1 gene-mutated advanced solid tumors, including glioma, that have recurred or progressed following standard therapy, or that have…
AI-generated summary
This study tests an oral drug called AG-120 (ivosidenib) in people with IDH1-mutated advanced solid tumors, including glioma. It enrolls adults whose disease has recurred or progressed after standard therapy and includes several expansion groups such as cholangiocarcinoma, chondrosarcoma, non-enhancing glioma, and other IDH1-mutated tumors. The study first uses a dose-escalation phase to find the maximum tolerated dose and a recommended Phase II dose, then expands at that dose to evaluate safety, tolerability, and any signs of clinical activity. The trial aims to learn how safe the drug is, how it behaves in the body, and whether it shows anticancer activity at the chosen dose. Key exclusions include recent anticancer therapy or investigational agents, certain heart conditions or QT prolongation risk, pregnancy, and untreated or recently treated brain metastases.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 77
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
77/100
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma +3
Eligibility
Inclusion Criteria: * Subjects must be able to understand the nature of this trial and provide written informed consent, prior to any study specific procedures; patients with Impaired Decision Making Capacity (IDMC)…
AI-generated summary
- This trial tests olaparib, a drug that may slow tumor growth, in adults with glioma, cholangiocarcinoma, or other solid tumors that have IDH1 or IDH2 mutations and have progressed after standard treatment.
- Participants are grouped into three cohorts: glioma, cholangiocarcinoma, and other IDH-mutant solid tumors, to see how they respond to olaparib.
- The study aims to learn the overall response rate, how long patients live without the disease getting worse, overall survival, duration of responses, and the safety of olaparib alone.
- Researchers will measure blood and tumor markers, including a molecule called 2HG, to see if these relate to treatment response.
- Key exclusions include active uncontrolled brain metastases, prior PARP inhibitor therapy, pregnancy, HIV infection on antiretroviral therapy, and other serious medical conditions.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 77
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
77/100
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis +29
Eligibility
Inclusion Criteria: * Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621K based on the presence of an actionable mutation as defined in…
AI-generated summary
This pediatric MATCH trial tests the drug ivosidenib (AG-120) in children and adolescents with advanced solid tumors, CNS tumors, lymphomas, or histiocytic disorders that have IDH1 mutations and have not responded to prior treatment. The study aims to see how often tumors shrink or disappear (objective response rate) and to learn about progression-free survival and safety in this group. Participants are aged 12 months to 21 years and must have measurable disease along with other health criteria. Ivosidenib is given by mouth once daily in 28-day cycles, for up to 2 years, to study its pharmacology and biomarkers of response. Key exclusions include pregnancy or breastfeeding, use of strong CYP3A4 inhibitors or inducers, prior exposure to IDH1 inhibitors, and receiving another investigational or anti-cancer drug at enrollment.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
AnHeart Therapeutics Inc.
Patient usefulness rating
40/100
Conditions
Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation
Eligibility
Inclusion Criteria: 1. Must be ≥18 years of age at the time of signing the informed consent form. 2. Must have locally advanced or metastatic solid tumors that have recurred or progressed…
AI-generated summary
- This open-label, early-phase trial tests an oral IDH1 inhibitor called AB-218 to see if it is safe, tolerable, how it behaves in the body, and whether it shows any early signs of anti-tumor activity in adults with advanced IDH1-mutant cholangiocarcinoma and other IDH1-mutant solid tumors after prior therapy.
- The study starts with a dose-escalation part testing three dose levels (125, 250, and 500 mg twice daily) using a 3+3 design, then moves to a dose-expansion part with two groups: cholangiocarcinoma and other IDH1-mutant solid tumors, to gather safety and preliminary efficacy data.
- Eligibility requires adults with confirmed IDH1-mutant tumors, measurable disease, adequate organ function, ECOG 0–1, and life expectancy over 3 months, among other criteria; patients must have had at least one prior therapy or be unsuitable for first-line intensive chemotherapy.
- Key exclusions include IDH1-mutant glioma or AML, significant cardiovascular disease, active infections, HIV, pregnancy, and certain drug interactions or QT prolongation risks.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 71
Patient usefulness rating
71/100
Conditions
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Eligibility
Inclusion Criteria: * Have nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation or ablative therapies * Have documented IDH1 gene-mutated disease from a tumor biopsy * Have an…
AI-generated summary
- This study tests the drug ivosidenib in Japanese adults whose cholangiocarcinoma cannot be removed and has an IDH1 mutation.
- Participants have already had 1–2 prior treatments and will take ivosidenib daily in 28-day cycles to evaluate safety and potential impact on survival.
- The trial will follow participants to learn overall survival and monitor side effects, with regular tumor assessments and health checks.
- Key exclusions include prior IDH inhibitors, active brain metastases needing steroids, pregnancy or plans to become pregnant, and certain heart or drug interaction risks (such as QT prolongation or strong CYP3A4 inducers).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 70
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
70/100
Conditions
Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
Eligibility
Inclusion Criteria: * Subjects must be able to understand the nature of this trial and provide written informed consent, prior to any study specific procedures. Patients with impaired decision making capacity (IDMC)…
AI-generated summary
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors is being studied. Conditions: Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm • Eligibility: Inclusion Criteria: * Subjects must be able to understand the nature of this trial and provide written informed consent, prior to any study specific procedures. Patients with impaired…. Goal: This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
47/100
Eligibility
Inclusion Criteria: * Male or female patients ≥ 18 years of age * Patients with a histologically confirmed solid tumor: * Tumor must harbor an IDH1-R132X mutation * Disease must be evaluable…
AI-generated summary
Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria: * Male or female patients ≥ 18 years of age * Patients with a histologically confirmed solid tumor: * Tumor must harbor an IDH1-R132X mutation *…. Goal: The primary objective of this study is: \- Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of BAY 1436032 in patients with isocitrate dehydrogenase-1 (IDH1)-R132X-mutant advanced solid tumors. The secondary objectives of this study are: * Evaluate the pharmacokinetics (PK) of BAY1436032 in patients with IDH1-R132X-mutant advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Bayer.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 68
Sponsor
Servier (Tianjin) Pharmaceutical Co. LTD.
Patient usefulness rating
68/100
Eligibility
Inclusion and exclusion criteria for treatment group Patients will be included if they meet all the following criteria: 1. Patients (female and male) aged ≥ 12 years at enrolment. 2. Patients with…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 63
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Patient usefulness rating
63/100
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Eligibility
Inclusion Criteria: * Age ≥18 years * Newly diagnosed AML or MDS-EB2 defined according to WHO criteria, with a documented IDH1 or IDH2 gene mutation (as determined by the clinical trial assay)…
AI-generated summary
The study is testing adding Ivosidenib for IDH1 mutations or Enasidenib for IDH2 mutations to standard chemotherapy in adults with newly diagnosed AML or MDS-EB2 who are candidates for intensive chemotherapy. It uses induction therapy, followed by consolidation therapy and then maintenance therapy, to see if the combination can control the disease more effectively and for a longer time. The trial is currently active but not recruiting. Key exclusions include prior chemotherapy for AML/MDS-EB2 (except certain agents), having both IDH1 and IDH2 mutations, APL, active infection, significant heart disease, and pregnancy or contraception requirements for participants.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 73
Sponsor
University of California, San Francisco
Patient usefulness rating
73/100
Conditions
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma +6
Eligibility
Inclusion Criteria: * Arm A Only: Participants must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma. * Arm B Only: WHO grades I-IV recurrent IDH1/2 mutant glioma.…
AI-generated summary
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas is being studied. Conditions: Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation +7 • Eligibility: Inclusion Criteria: * Arm A Only: Participants must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma. * Arm B Only: WHO grades I-IV…. Goal: This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of California, San Francisco.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
J-Pharma Co., Ltd.
Patient usefulness rating
91/100
Conditions
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Eligibility
Inclusion Criteria: \- Individuals are eligible to be included in the study only if all of the following criteria apply: 1. At least 18 years of age inclusive at the time of…
AI-generated summary
This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
89/100
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Eligibility
Inclusion Criteria: * Histologically-proven glioblastoma (World Health Organization \[WHO\] 2021 criteria) * Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO) criteria * No IDH mutation (IDH1 R132H negative by immunohistochemistry…
AI-generated summary
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma is being studied. Conditions: Progressive Glioblastoma, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Histologically-proven glioblastoma (World Health Organization \[WHO\] 2021 criteria) * Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO) criteria * No IDH mutation (IDH1…. Goal: This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
84/100
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver +39
Eligibility
Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load…
AI-generated summary
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Centre Hospitalier Universitaire de Besancon
Patient usefulness rating
83/100
Conditions
Advanced Biliary Tract Carcinoma
Eligibility
Inclusion Criteria: 1. Signed and dated informed consent 2. Histologically confirmed biliary tract carcinoma: intra/extrahepatic cholangiocarcinoma (note that gallbladder carcinoma are not eligible) 3. Locally advanced unresectable or metastatic 4. Patient who…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Diakonos Oncology Corporation
Patient usefulness rating
83/100
Conditions
Glioblastoma (GBM)
Eligibility
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age 18 years…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
L & L Bio Co., Ltd., Ningbo, China
Patient usefulness rating
82/100
Eligibility
Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in the past 2 weeks.…
AI-generated summary
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Dana-Farber Cancer Institute
Patient usefulness rating
82/100
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma +10
Eligibility
Inclusion Criteria: * Frozen biopsy consistent with glioma by neuropathologist at the time of the first surgery in this longitudinal trial. Biopsy confirmation of glioma or infiltrative glioma at time of surgery…
AI-generated summary
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 is being studied. Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma +11 • Eligibility: Inclusion Criteria: * Frozen biopsy consistent with glioma by neuropathologist at the time of the first surgery in this longitudinal trial. Biopsy confirmation of glioma or infiltrative glioma…. Goal: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Servier Affaires Médicales
Patient usefulness rating
82/100
Conditions
Cholangiocarcinoma
Eligibility
Inclusion Criteria: * Diagnosis of nonresectable or metastatic Cholangiocarcinoma (CCA), not eligible for curative-intent resection, transplantation, or ablative therapies * Have a documented IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease…
AI-generated summary
This is an early access study testing the drug ivosidenib in adults with previously treated, locally advanced or metastatic cholangiocarcinoma that has an IDH1 mutation. The study is open-label and single-arm: eligible participants receive ivosidenib 500 mg daily in 28-day cycles to look at safety and effectiveness. Researchers want to learn whether ivosidenib remains safe and helpful in this setting and how it affects patients’ quality of life, with regular visits and assessments during and after treatment. Key exclusions include prior IDH1 inhibitors, brain metastases requiring steroids, active hepatitis B or C or HIV infection, recent systemic therapy or major surgery, transplant, and pregnancy or breastfeeding.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
81/100
Conditions
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Eligibility
Inclusion Criteria: * Patients with histologically confirmed, newly diagnosed, supratentorial glioblastoma or gliosarcoma who have undergone gross total tumor resection or near gross total resection (resection of \>85% of enhancing tumor demonstrated…
AI-generated summary
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma +1 • Eligibility: Inclusion Criteria: * Patients with histologically confirmed, newly diagnosed, supratentorial glioblastoma or gliosarcoma who have undergone gross total tumor resection or near gross total resection (resection of \>85%…. Goal: This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Leland Metheny.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Orbus Therapeutics, Inc.
Patient usefulness rating
80/100
Conditions
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype +3
Eligibility
Inclusion Criteria: * Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021 tumor classification. * Completed…
AI-generated summary
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma is being studied. Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme +4 • Eligibility: Inclusion Criteria: * Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021…. Goal: The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Orbus Therapeutics, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
78/100
Eligibility
Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of one of the following: * Glioblastoma, IDH-wildtype * Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO classification) * Measurable disease…
AI-generated summary
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of one of the following: * Glioblastoma, IDH-wildtype * Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO…. Goal: The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Heinrich-Heine University, Duesseldorf
Patient usefulness rating
77/100
Conditions
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Eligibility
Inclusion Criteria: * Subjects must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC), prior to the initiation of any study-specific procedures * MDS, CMML or sAML…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Sunnybrook Health Sciences Centre
Patient usefulness rating
76/100
Conditions
Low-grade Glioma
Eligibility
Inclusion Criteria: 1. Be at least 12 years of age; 2. Diagnosed with: 1. Cohort A (pre-surgical): Suspected LGG (oligodendroglioma or astrocytoma), based on any combination of histological, molecular, radiological, and/or clinical…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 75
Sponsor
Cecilia Soderberg-Naucler
Patient usefulness rating
75/100
Conditions
Glioblastoma Multiforme
Eligibility
Inclusion Criteria: 1. Patients aged 18 years or older 2. Patients with newly diagnosed glioblastoma, IDH 1 wt, WHO grade IV 3. Radical resection 4. Concomitant treatment with temozolomide and radiation therapy…
AI-generated summary
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Patients aged 18 years or older 2. Patients with newly diagnosed glioblastoma, IDH 1 wt, WHO grade IV 3. Radical resection 4. Concomitant treatment with…. Goal: This study is a multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy and safety of the anti-CMV drug valganciclovir vs placebo as add-on therapy in patients with glioblastoma. Valganciclovir is approved for treatment of cytomegalovirus (CMV) infections, but may also have anti-tumoral effects. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cecilia Soderberg-Naucler.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 75
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
75/100
Conditions
Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma +1
Eligibility
* INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation…
AI-generated summary
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype is being studied. Conditions: Glioma, Glioblastoma, High Grade Glioma +2 • Eligibility: * INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate…. Goal: Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Virogin Biotech Canada Ltd
Patient usefulness rating
75/100
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Eligibility
Inclusion Criteria: 1. Signed written informed consent. 2. Males or females aged 18 years and older. 3. Performance status: Eastern Cooperative Oncology Group (ECOG) 0 or 1. 4. For subject in Cohort…
AI-generated summary
The trial tests VG161, injected directly into tumors, as a standalone treatment or in combination with Nivolumab for adults with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). It starts with a safety run-in and then includes monotherapy groups for HCC and ICC to assess safety and anti-tumor activity. There is also a group combining VG161 with IV Nivolumab to evaluate potential added benefit. The study uses predefined stopping rules to learn whether the treatment provides meaningful responses or progression-free survival, and to decide if the trial should continue. Eligible participants are adults 18+, ECOG 0–1, with measurable injectable disease and adequate liver function; key exclusions include active infections, certain brain metastases, recent major surgery, and use of systemic immunosuppressants or anticoagulants.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 73
Sponsor
National Cancer Institute (NCI)
Patient usefulness rating
73/100
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Eligibility
Inclusion Criteria: * PRIOR TO STEP 1 REGISTRATION: * No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other…
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 72
Sponsor
GT Medical Technologies, Inc.
Patient usefulness rating
72/100
Eligibility
Inclusion Criteria: 1. All patients must be ≥ 18 years of age 2. Histopathological and molecular confirmation of newly diagnosed GBM using IDH mutation testing (such as immunohistochemistry for IDH1 R132H) must…
AI-generated summary
GammaTile and Stupp in Newly Diagnosed GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. All patients must be ≥ 18 years of age 2. Histopathological and molecular confirmation of newly diagnosed GBM using IDH mutation testing (such as immunohistochemistry…. Goal: In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; GT Medical Technologies, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
NOT_YET_RECRUITINGRating 70
Sponsor
Royal North Shore Hospital
Patient usefulness rating
70/100
Conditions
Glioblastoma, Glioblastoma Multiforme (GBM)
Eligibility
Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of radiotherapy with clinical or…
AI-generated summary
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme (GBM) • Eligibility: Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of…. Goal: This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Royal North Shore Hospital.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 69
Sponsor
Sun Yat-sen University
Patient usefulness rating
69/100
Eligibility
Inclusion Criteria: * Understood and Signed an informed consent form., with good compliance * Age: 18-75 years old；.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2；Life expectancy of at least…
AI-generated summary
Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Understood and Signed an informed consent form., with good compliance * Age: 18-75 years old；.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2；Life…. Goal: Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sun Yat-sen University.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 67
Sponsor
Beijing Tiantan Hospital
Patient usefulness rating
67/100
Conditions
Glioblastoma Multiforme of Brain
Eligibility
Inclusion Criteria: 1. Age from 18 to 75 years (including 18 and 75 years old); 2. Newly-diagnosed glioblastoma confirmed by histopathological exams; 3. IDH1- and IDH2-wild-type gliomas; 4. Extent of resection of…
AI-generated summary
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery is being studied. Conditions: Glioblastoma Multiforme of Brain • Eligibility: Inclusion Criteria: 1. Age from 18 to 75 years (including 18 and 75 years old); 2. Newly-diagnosed glioblastoma confirmed by histopathological exams; 3. IDH1- and IDH2-wild-type gliomas; 4.…. Goal: This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to treat adult postoperative patients with newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ) chemotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Beijing Tiantan Hospital.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
ACTIVE_NOT_RECRUITINGRating 63
Sponsor
Chang Gung Memorial Hospital
Patient usefulness rating
63/100
Conditions
Myeloproliferative Neoplasms
Eligibility
Inclusion Criteria: 1. Male and female patients aged ≥ 20 years. 2. Patient who had a confirmed diagnosis according to the 2016 revised WHO criteria with a Ph (-) MPN. Exclusion Criteria:…
AI-generated summary
The Registry of Patients With MPNs in Taiwan is an observational registry that collects clinical data, molecular characteristics, treatment details, and responses in people with myeloproliferative neoplasms. It aims to understand how MPNs are diagnosed and treated in Taiwan, including high-molecular-risk gene information, and to track complications and survival. Eligible participants are adults 20 years and older with a confirmed Ph(-) MPN by the 2016 WHO criteria, and they must consent to participate; those who don’t meet criteria or don’t sign consent are excluded. The study is currently active but not recruiting.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
University of Florida
Patient usefulness rating
51/100
Conditions
Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
Eligibility
Inclusion Criteria: * Age ≥18 years * Histologically confirmed clinical diagnosis of incurable cancer * Confirmed diagnosis of uveal melanoma, mesothelioma, renal cell carcinoma (clear cell subtype), or cholangiocarcinoma (Cohort A only)…
AI-generated summary
- This trial tested niraparib, a PARP inhibitor, in adults whose tumors have BAP1 or other DNA damage repair (DDR) gene mutations.
- It was open-label and non-randomized, sponsored by the University of Florida, to see if niraparib can shrink DDR-deficient cancers.
- Eligible participants included adults with incurable cancers such as uveal melanoma, mesothelioma, clear cell renal cell carcinoma, or cholangiocarcinoma (cohort A) with a confirmed DDR mutation (with a separate cohort for additional DDR criteria).
- Exclusions included prior PARP inhibitor therapy and known BRCA1/2 mutations; the trial has been completed.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Case Comprehensive Cancer Center
Patient usefulness rating
51/100
Conditions
Glioblastoma, Brain Tumor
Eligibility
Inclusion Criteria: * Patients must have histologically or cytologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external beam fractionated radiotherapy and temozolomide…
AI-generated summary
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma is being studied. Conditions: Glioblastoma, Brain Tumor • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external beam…. Goal: Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
DelMar Pharmaceuticals, Inc.
Patient usefulness rating
49/100
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, GBM +1
Eligibility
Inclusion Criteria: 1. Patient must agree to testing of GBM tumor promoter methylation status of the MGMT gene and tumor (IDH1) gene mutation status. Tissue may be tested at study entry, if…
AI-generated summary
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioma +2 • Eligibility: Inclusion Criteria: 1. Patient must agree to testing of GBM tumor promoter methylation status of the MGMT gene and tumor (IDH1) gene mutation status. Tissue may be tested…. Goal: This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now has progressive disease during or after bevacizumab. A total of up to 180 eligible patients with recurrent/progressive GBM or GS will be randomized to receive either the investigational drug (VAL-083) or "Investigator's choice of salvage therapy" as a contemporaneous control, in a 2:1 fashion. Phase/Status/Sponsor: Unknown phase; TERMINATED; DelMar Pharmaceuticals, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
NYU Langone Health
Patient usefulness rating
45/100
Conditions
MGMT-unmethylated Glioblastoma (GBM), GBM
Eligibility
Inclusion Criteria: * Male or female subjects aged ≥18 years. * Histopathological evidence of glioblastoma or gliosarcoma, WHO grade IV. * Tumor MGMT promoter DNA not methylated (i.e., unmethylated) by central testing.…
AI-generated summary
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma is being studied. Conditions: MGMT-unmethylated Glioblastoma (GBM), GBM • Eligibility: Inclusion Criteria: * Male or female subjects aged ≥18 years. * Histopathological evidence of glioblastoma or gliosarcoma, WHO grade IV. * Tumor MGMT promoter DNA not methylated (i.e.,…. Goal: This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year. Phase/Status/Sponsor: Unknown phase; COMPLETED; NYU Langone Health.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
45/100
Conditions
Cholangiocarcinoma, Cancer of the Head of the Pancreas
Eligibility
1. Tumor genotyping in bile samples: Inclusion criteria : * patients surgically treated for malignant biliary stricture related to cholangiocarcinoma or cancer of the head of the pancreas. * diagnosis of cholangiocarcinoma…
AI-generated summary
The study tested whether bile samples can reveal the tumor mutation profile and genotype in people with malignant biliary strictures (cholangiocarcinoma or cancer of the head of the pancreas). It also looked at whether levels of VEGF and MMPs in bile could help diagnose these conditions. For tumor genotyping, 10 adults who were surgically treated for malignant biliary stricture with confirmed cancer were included; for biomarkers, bile collected during ERCP from 100 adults (50 malignant, 50 benign) was analyzed. Eligible participants were adults who consented to storage of bile and tissue in the hospital tissue bank; those who did not consent were excluded. The trial is completed.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
PIQUR Therapeutics AG
Patient usefulness rating
44/100
Conditions
Glioblastoma Multiforme
Eligibility
Inclusion Criteria: 1. Patients with histologically confirmed glioblastoma at first progression following or during standard temozolomide chemoradiotherapy (TMZ/RTTMZ) 2. older than 18 years of age 3. Radiographic demonstration of disease progression by…
AI-generated summary
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Patients with histologically confirmed glioblastoma at first progression following or during standard temozolomide chemoradiotherapy (TMZ/RTTMZ) 2. older than 18 years of age 3. Radiographic demonstration…. Goal: PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase) and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at pharmacodynamically active concentrations. This study plans to evaluate PQR309 in treatment of patients with first progression of glioblastoma. Phase/Status/Sponsor: Unknown phase; TERMINATED; PIQUR Therapeutics AG.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Dana-Farber Cancer Institute
Patient usefulness rating
42/100
Eligibility
Inclusion Criteria: * All participants must meet the following criteria on screening examination to be eligible to participate in the study: * Participants must be able to understand and willing to sign…
AI-generated summary
Abemaciclib + Pembrolizumab In Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * All participants must meet the following criteria on screening examination to be eligible to participate in the study: * Participants must be able to understand…. Goal: This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. This study will involve participants with recurrent glioblastoma at their first relapse enrolled in two arms including patients who require reoperation and patients not requiring surgery. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Dana-Farber Cancer Institute.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Patient usefulness rating
40/100
Conditions
Recurrent Glioblastoma
Eligibility
Inclusion Criteria: 1. Provision of signed and dated informed consent prior to any study specific procedures, sampling or analyses. 2. Aged at least 18 years old 3. Patients must have a histologically…
AI-generated summary
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent prior to any study specific procedures, sampling or analyses. 2. Aged at least 18 years old 3. Patients…. Goal: This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy. Phase/Status/Sponsor: Unknown phase; TERMINATED; PharmAbcine.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
Washington University School of Medicine
Patient usefulness rating
40/100
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade IV
Eligibility
Inclusion Criteria: * Newly diagnosed histologically confirmed glioblastoma multiforme (WHO grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be excluded. * Patients who…
AI-generated summary
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma Multiforme, Astrocytoma, Grade IV • Eligibility: Inclusion Criteria: * Newly diagnosed histologically confirmed glioblastoma multiforme (WHO grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or IDH2 mutant, will not be…. Goal: The early clinical development paradigm for chemotherapeutic agents has significantly influenced the development of therapeutic cancer vaccines. However, there are major differences between these two classes of therapeutics that have important implications for early clinical development. Phase/Status/Sponsor: Unknown phase; TERMINATED; Washington University School of Medicine.
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.
Sponsor
GT Medical Technologies, Inc.
Patient usefulness rating
38/100
Eligibility
Inclusion Criteria: 1. Patients aged 18 years old and above. Eligibility is restricted to this age group given that the battery of neurocognitive tests utilized in this protocol are not developed or…
AI-generated summary
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Patients aged 18 years old and above. Eligibility is restricted to this age group given that the battery of neurocognitive tests utilized in this protocol…. Goal: To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile therapy. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; GT Medical Technologies, Inc..
This summary may be inaccurate. Verify against ClinicalTrials.gov.
Primary source facts: ClinicalTrials.gov metadata.